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CASE REPORTAmlodipine-induced hypersensitivity
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We report the case of a drug-inducedmorbilliform
eruption associated with amlodipine that mimicked
the presentation of CD301 mycosis fungoides, both
clinically and histologically. The rash resolved after
discontinuation of the amlodipine, suggesting that
the event was a rare CD301 pseudolymphoma
cutaneous reaction to this drug.CASE REPORT
A 76-year-old white woman presented with a
3-month history of a pruritic, diffuse morbilliform
eruption consisting of erythematous papules and
plaques with cigarette-paper scale coalescing to
cover more than 80% body surface area (Fig 1).
Based on clinical presentation, the initial differential
diagnosis included a drug eruption or urticarial
bullous pemphigoid. The patient’s amlodipine dose
was doubled by her primary care physician
11 months after initially prescribing 5 mg daily, and
she was maintained on 2 additional antihypertensive
medications, metoprolol and losartan. Two days
after adjustment in medications, the patient was
seen in the emergency room for exacerbation of
the rash on her face. The patient’s primary care
physician subsequently discontinued amlodipine
and initiated nifedipine to control the patient’s blood
pressure.
The patient’s medical history was significant for
graft-versus-host disease (GVHD) 24 years prior after
a bone marrow transplant for chronic myelogenous
leukemia, diabetes, and amlodipine-associated
flushing and ankle edema. The patient was takingthe Departments of Dermatology and Cutaneous Biology,a
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leukemia has been in remission for the last 24 years
after transplant and requires no medication.
Whole-body positron emission tomographye
computed tomography found a mildly hypermeta-
bolic subcentimeter left cervical level Ib lymph node
with standardized uptake value of a maximum of
1.69. Flow cytometric analysis of peripheral blood
showed a slightly elevated CD4/CD8 ratio of 5.4 but
otherwise did not show an immunophenotypically
abnormal cell population. T-cell receptor g assay of
the blood was positive for a polyclonal T-cell
receptor g gene rearrangement.
A biopsy of the right thigh found superficial
perivascular and interstitial dermatitis with atypical
lymphocytes. Spongiosis of the overlying epidermis
was notedwith subcorneal collections of neutrophils
along with subtle epidermotropism (Fig 2).
Immunostaining found that the large atypical cells
were strongly CD301 and weakly CD31. CD30
highlighted a portion of the epidermotropic infiltrate
(Fig 3). The pathology-based differential diagnoses
included lymphomatoid papulosis, lymphomatoid
drug reaction, and less likely CD301-transformed
mycosis fungoides. A clonal rearrangement of the
T-cell receptor g gene was detected by polymerase
chain reaction in the skin.
The patient was prescribed mechlorethamine gel
0.016% 3 times a week and showed improvement onJAAD Case Reports 2016;2:320-2.
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Fig 1. Pruritic erythematous scaly papules coalescing into
plaques on the patient’s dorsal right thigh.
Fig 2. Intact stratum corneum and Pautrier’s microabscess
within the viable epidermis. Vacuolar interface changes
and atypical hyperchromatic lymphocytes in the papillary
dermis.
Fig 3. Prominent CD301 staining is seen both perivascu-
larly at the dermo-epidermal junction and at viable
epidermis.
Fig 4. Diffuse mild xerosis after rash on resolution of the
original eruption.
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persisted. Mechlorethamine was continued for
her rash, and nifedipine was discontinued and
hydralazine was initiated to control the patient’s
hypertension. Four weeks later, the violaceous
erythema and papules disappeared, and no other
signs or symptoms of dermatitis remained (Fig 4).
The patient was instructed to discontinue mechlor-
ethamine use at this point. She remains without
evidence of lymphoproliferative disease. The patient
has not been rechallenged with amlodipine or
nifedipine.DISCUSSION
Cutaneous drug hypersensitivity reactions ac-
count for roughly 3% of hospitalizations,1 although
this finding may be an underestimation because of
variability in the presentation, identification, and
reporting of drug-induced cutaneous rashes.
Drug-induced reactions usually appear within weeksor months of administration of the offending drug
and resolve within 2 months of withdrawal.1,2 In
rare cases, these reactions present as a CD301
lymphocytic infiltrate that resembles clinical and
histologic variants of cutaneous T-cell lymphoma.1
Amlodipine works by blocking the calcium ion
channels and inhibiting the actin-myosin complex and
cardiac muscle contraction.3 Amlodipine-induced
CD301 drug reactions are reported in the literature,
but the mechanism is not well understood.2 It is
hypothesized that the implicated drug plays a role in
diminishing T-cell suppressor function, which
leads to an exaggerated T-helper cell response
to various antigens.4 Other antihypertensive drugs
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hyperplasia in addition to calcium channel blockers
include diuretics, angiotensin-converting enzyme
inhibitors, b-blockers and a-antagonists.5
The cutaneous manifestations of pseudolym-
phoma induced by amlodipine range from diffuse
desquamated erythema to more focal papules
and annular plaques.6,7 The diagnosis for our
patient was more consistent with a drug-induced
pseudolymphoma rather than a nonspecific drug
hypersensitivity syndrome. Histologic examination
found features of cutaneous T-cell lymphoma, and
the cutaneous reaction resolved once the drug was
stopped.8 A rare finding, this case had similarities to
previously reported cases in which amlodipine
induced a pseudolymphomatous CD301 cutaneous
eruption. Kabashima et al9 described a case of a
74-year-old man with a 10-month history of red
papules and erythematous plaques who had been
taking 5 mg of amlodipine daily for the last
12 months. Upon biopsy, a lymphocytic infiltrate
with large irregular hyperchromatic nuclei in
the papillary dermis was noted with admixed
eosinophils, an elevated CD41/CD81 ratio, and a
large number of CD301 cells. Similarly, Fukamachi
et al10 described the case of a 70-year-old man with a
4-month history of scaly erythematous plaques
primarily on his trunk and extremities who had
been taking amlodipine for 1 year. Biopsy found a
CD41 and CD301 infiltrate with mild hyperkeratosis
and a dense lymphocytic infiltrate mixed with
eosinophils in the middle to papillary dermis. Both
of these CD301 amlodipine-induced reactions
resolved within 3 weeks to 2 months after stopping
amlodipine.1,9,10
In our patient, an increased ratio of CD4/CD8 and
a clonal T-cell population were detected in the blood
before the discontinuation of nifedipine. Similar
findings were noted in a case presented by
Plaza et al,4 in which 15 cases of drug-induced
lymphomatoid hypersensitivity with reversible
T-cell dyscrasias were found to be positive for
a b T-cellereceptor gene rearrangement. The
implicated drugs in these cases were nifedipine
and amlodipine; a monoclonal population was
observed in the case associated with nifedipine.4
In the case presented above, our patient’s past
GVHD may have increased her susceptibility to thisepisode of T-cell dyscrasia exacerbated by the
administration of amlodipine. Although our patient’s
GVHD was a remote clinical diagnostic possibility
based on her initial presentation, the histologic
findings were not compatible with recurrence.
The above case illustrates the ability of amlodi-
pine to induce a CD301 lymphomatoid drug
reaction. Careful correlation of both clinical and
histologic data should be made to differentiate a
primary lymphocytic proliferative process from a
reactive lymphomatoid drug reaction in the setting of
CD30 positivity. In patients with similar clinical
presentations, this case underscores the importance
of carefully considering the patient’s medication list
to identify any potential iatrogenic etiologies of the
cutaneous findings. If amlodipine or any other
calcium channel blocker is suspected as the causa-
tive agent, the medication should be discontinued
and then rechallenged if appropriate, or an alterna-
tive antihypertensive therapy should be initiated.
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